1. Progression-free survival improved significantly in patients with low-volume disease who received abiraterone and radiotherapy. 2. The addition of radiotherapy ...
1. There was no significant difference in metastasis-free survival between the ADT and non-ADT groups over 10 years. 2. Adverse ...
1. A combination of androgen deprivation therapy, docetaxel, and abiraterone (“triplet therapy”) had the best overall survival and progression-free survival ...
1. Abiraterone acetate plus standard treatment significantly increased length of metastasis-free survival in men with non-metastatic prostate cancer compared to ...
1. In this retrospective cohort study, there was no significant difference in all-cause mortality between patients with prostate cancer and ...
1. In a retrospective review of over 30 000 prostate cancer patients, adding radiotherapy to androgen deprivation therapy (ADT) was associated ...
Image: PD 1. Androgen deprivation therapy increases the risk of acute kidney injury in patients with non-metastatic prostate cancer. 2. ...
